Free Trial

OraSure Technologies Q2 2024 Earnings Report

OraSure Technologies logo
$3.43 -0.06 (-1.72%)
As of 03/28/2025 04:00 PM Eastern

OraSure Technologies EPS Results

Actual EPS
$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OraSure Technologies Revenue Results

Actual Revenue
$54.34 million
Expected Revenue
$53.35 million
Beat/Miss
Beat by +$990.00 thousand
YoY Revenue Growth
N/A

OraSure Technologies Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

OraSure Technologies Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
OraSure board authorizes $40M stock repurchase program
OraSure Announces $40 Million Stock Repurchase Program
See More OraSure Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OraSure Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OraSure Technologies and other key companies, straight to your email.

About OraSure Technologies

OraSure Technologies (NASDAQ:OSUR), together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

View OraSure Technologies Profile

More Earnings Resources from MarketBeat